NCT06468423

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: RESnTEC, Institute of Research · Academic / Other
• Sex: All
• Age: 2 Years – 15 Years
• Healthy volunteers: Not accepted

Summary

This study was planned to compare deferasirox and desferrioxamine in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Choosing an effective iron chelator is crucial to increasing iron chelation therapy compliance. Not much local data exists in Pakistan comparing the effectiveness of deferasirox (DFX) and desferrioxamine (DFO), so, this study would be helpful in providing baseline data and formulating new protocols for iron chelation therapy, in which DFX may be a useful oral alternative to parenteral DFO.

Conditions

• Pateints of β-thalassemia Major With Iron Overload

Interventions

Type	Name	Description
DRUG	Deferasirox (DFX)	Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
DRUG	Deferoxamine (DFO)	DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.

Timeline

• Start date: 2023-01-01
• Primary completion: 2023-09-30
• Completion: 2023-09-30
• First posted: 2024-06-21
• Last updated: 2024-06-21

Locations

1 site across 1 country: Pakistan